Mereo BioPharma Group (MREO) Stock Price, News & Analysis

Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $3.65 to $3.81
• 50-Day Range: $3.33 to $4.62
• 52-Week Range: $3.17 to $5.02
• Volume: 831,486 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $2.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Buy

Mereo BioPharma Group Stock Analysis - MarketRank™

Mereo BioPharma Group scored higher than 66% of companies evaluated by MarketBeat, and ranked 377th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Mereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mereo BioPharma Group has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -83.33%

Earnings Growth

Earnings for Mereo BioPharma Group are expected to decrease by -83.33% in the coming year, from $0.06 to $0.01 per share.

Price to Book Value per Share Ratio

Mereo BioPharma Group has a P/B Ratio of 10.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.59% of the outstanding shares of Mereo BioPharma Group have been sold short.

Short Interest Ratio / Days to Cover

Mereo BioPharma Group has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Mereo BioPharma Group has recently decreased by 11.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mereo BioPharma Group does not currently pay a dividend.

Dividend Growth

Mereo BioPharma Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.59% of the outstanding shares of Mereo BioPharma Group have been sold short.

Short Interest Ratio / Days to Cover

Mereo BioPharma Group has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Mereo BioPharma Group has recently decreased by 11.43%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.95

News Sentiment

Mereo BioPharma Group has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Mereo BioPharma Group this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mereo BioPharma Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $236,602.00 in company stock.

Percentage Held by Insiders

Only 4.13% of the stock of Mereo BioPharma Group is held by insiders.

Percentage Held by Institutions

62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MREO Stock Analysis - Frequently Asked Questions

How have MREO shares performed this year?

Mereo BioPharma Group's stock was trading at $2.31 at the start of the year. Since then, MREO stock has increased by 61.0% and is now trading at $3.72.
View the best growth stocks for 2024 here.

How were Mereo BioPharma Group's earnings last quarter?

Mereo BioPharma Group plc (NASDAQ:MREO) announced its quarterly earnings data on Thursday, September, 7th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02).

When did Mereo BioPharma Group IPO?

Mereo BioPharma Group (MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

Who are Mereo BioPharma Group's major shareholders?

Mereo BioPharma Group's top institutional shareholders include Janus Henderson Group PLC (8.80%), Frazier Life Sciences Management L.P. (3.63%), Clearline Capital LP (2.31%) and Acuta Capital Partners LLC (0.90%). Insiders that own company stock include Denise Scots-Knight, Charles Sermon, Christine Ann Fox, John A Lewicki, Alexandra Hughes-Wilson and Deepika Pakianathan.
View institutional ownership trends.

How do I buy shares of Mereo BioPharma Group?

Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR).

Company Calendar

• Last Earnings: 9/07/2023
• Today: 11/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MREO
• CUSIP: N/A
• CIK: 1719714
• Web: www.mereobiopharma.com
• Phone: 44-33-3023-7300
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +101.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.86
• Quick Ratio: 4.86

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 288.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.36 per share
• Price / Book: 10.33

Miscellaneous

• Outstanding Shares: 775,730,000
• Free Float: 134,464,000
• Market Cap: $2.89 billion
• Optionable: Optionable
• Beta: N/A